Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Jun 9, 2026

•

3 min read

Biotech & Pharma Updates | June 9, 2026

🧬 GSK to acquire Nuvalent Bio for $10.6B, securing precision oncology pipeline in industry's second-largest deal, Parabilis Medicines plans up to $636.8M IPO, advancing rare tumor candidate zolucatetide, Gilead, Merck & Co.'s (islatravir/lenacapavir) meets primary endpoint in Ph3 trials for human immunodeficiency virus type 1

Christian Cuchapin, +1

Jun 8, 2026

•

4 min read

Biotech & Pharma Updates | June 8, 2026

🧬 Eli Lilly's retatrutide achieves 30.3% weight reduction at 104 weeks in Ph3 trial for obesity, Johnson & Johnson acquires Firefly Bio for $1B upfront to access DAC platform targeting KRAS-driven tumors, Hikma Pharmaceuticals invests $267M to expand two Ohio manufacturing sites, adding 350 jobs

Christian Cuchapin, +1

Jun 5, 2026

•

3 min read

Biotech & Pharma Updates | June 5, 2026

🧬 Pfizer partners with Chai Discovery on AI-driven drug discovery using custom and Chai-3 models, Hikma Pharmaceuticals wins unanimous Supreme Court ruling in landmark skinny labels patent case against Amarin, Otsuka Pharmaceuticals' Voyxact (sibeprenlimab) Ph3 data show kidney function stabilization in immunoglobulin A nephropathy

Christian Cuchapin, +1

Jun 4, 2026

•

3 min read

Biotech & Pharma Updates | June 4, 2026

🧬 Innovent Biologics' (arcotatug tavatecan) hits Ph3 win in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma, Alnylam Pharmaceuticals, Inceptive Nucleics partner on AI-driven siRNA drug discovery, $30M upfront, up to $2B total, Parabilis plans up to $476M IPO, advancing peptide drug zolucatetide for desmoid tumors

Christian Cuchapin, +1

Jun 3, 2026

•

3 min read

Biotech & Pharma Updates | June 3, 2026

🧬 Legend Biotech's (LB2501) achieves 100% response rate in Ph1 non-Hodgkin lymphoma in vivo CAR T study, NewLimit raises $435M Series C, advancing epigenetic reprogramming medicine toward human trials, Eli Lilly, Ascidian Therapeutics partner on RNA exon editing for kidney diseases, up to $1.9B

Christian Cuchapin, +1

Jun 2, 2026

•

4 min read

Biotech & Pharma Updates | June 2, 2026

🧬 Moderna, Merck & Co.'s (intismeran autogene) plus Keytruda shows 49% recurrence risk reduction in Ph2b high-risk melanoma, Bristol Myers Squibb's (izalontamab brengitecan) Ph3 trial shows 40% reduced death risk in triple-negative breast cancer, Rallybio merges with Avenzo Therapeutics in reverse merger, backed by $215M private placement

Christian Cuchapin, +1

Jun 1, 2026

•

4 min read

Biotech & Pharma Updates | June 1, 2026

🧬 Eli Lilly's Kelonia Therapeutics' (KLN-1010) shows 100% response rate in Ph1 relapsed or refractory multiple myeloma trial, Revolution Medicines' daraxonrasib nearly doubles survival in Ph3 metastatic pancreatic cancer with KRAS mutation, Gilead's TUB-040 (NaPi2b-targeting ADC) shows 61% tumor response in Ph1 platinum-resistant ovarian cancer trial

Christian Cuchapin, +1

Long Form Content

The Most Skeptical Buyer - Selling To Scientists

May 30, 2026

•

8 min read

The Most Skeptical Buyer - Selling To Scientists

Selling to Scientists & Technical Industries

Anis Fahandej-Sadi

May 29, 2026

•

3 min read

Biotech & Pharma Updates | May 29, 2026

🧬 Pfizer, Innovent Biologics strike $10B cancer deal covering 12 ADC and multispecific antibody programs, $650M upfront, AstraZeneca's Imfinzi (durvalumab) wins FDA approval for BCG-naïve high-risk non-muscle-invasive bladder cancer after Ph3 win, Replimune resubmits RP1 melanoma BLA for third time following major FDA leadership shakeup

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | June 9, 2026

Biotech & Pharma Updates | June 8, 2026

Biotech & Pharma Updates | June 5, 2026

Biotech & Pharma Updates | June 4, 2026

Biotech & Pharma Updates | June 3, 2026

Biotech & Pharma Updates | June 2, 2026

Biotech & Pharma Updates | June 1, 2026

The Most Skeptical Buyer - Selling To Scientists

Biotech & Pharma Updates | May 29, 2026

TLDR Biotech

FAQ

Media Partners